Work performed: Purification of proteins.
Main results achieved:
a) Expression, purification, and characterisation of Als3 protein (316 amino acids) from Escherichia coli.
Work performed: Formulation of liposome as a vaccine candidate.
Main results achieved:
a) Chemical, and site-specific modification of proteins from C. albicans (Als3, Sap2 and Clys).
b) Protocol for the formulation of a liposome-conjugated vaccine candidate containing modified proteins (Als3, Sap2 and Clys) from C. albicans.
Work performed: Evaluation of the in vivo efficacy of the vaccine candidates.
Main results achieved:
a) The evaluation of the liposome-conjugate formulation (first batch) containing alum as adjuvant was performed in vivo using an established murine model of systemic candidiasis. Mice were immunised at week 2 and week 4 via intramuscular administration.
b) The evaluation of the liposome-conjugate formulation (second batch) containing CAF01 as adjuvant was performed in vivo using an established murine model of systemic candidiasis. Mice were immunised at week 2 and week 4 via intramuscular administration.
Work performed: Exploitation and dissemination of results.
Main results achieved:
a) Oral presentation in the Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King´s College London, 3 July 2023. “Multicomponent protein vaccine against C. albicans”.
b) Oral presentation at the King´s College London Soft Matter Meeting, 21 February 2023. “Multicomponent protein vaccine against C. albicans”.
c) Oral presentation in the Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King´s College London, 18 July 2022. “Design and synthesis of a multicomponent protein system”.
